EPCORE FL-2: A phase 3 trial of epcoritamab with rituximab and lenalidomide in people with untreated follicular lymphoma

This trial aims to see how effective epcoritamab in combination with rituximab and lenalidomide is in people with previously untreated follicular lymphoma.

You can share the following clinicaltrials.gov Identifier with your medical team so they can find out more about the trial: NCT06191744

Trial aim and background  

The aim of this trial to see how effective the treatment epcoritamab is when given in combination with intravenous rituximab and oral lenalidomide. It will assess any change in disease condition, as well as any adverse effects. 

People in the trial will be entered into one of four groups, and each group will receive a different treatment. All participants will receive rituximab and lenalidomide, but some may also receive epcoritamab. They may also receive investigators choice of chemotherapy. Treatment will last for a maximum of 120 weeks.

Epcoritamab is given subcutaneously and is a type of targeted treatment called a bispecific antibody, which is a new class of immunotherapy drug. Bispecific antibodies work by attaching to two targets, one on the surface of lymphoma cells and one on the surface of T cells (part of the immune system).

Who can enter 

Adults with classic follicular lymphoma at stage 2, 3 of 4 may be eligible for this trial.

Locations 

Recruitment is taking place at the following UK locations:

  • Derriford Hospital, Plymouth
  • Hammersmith Hospital, London
  • Leeds Teaching Hospitals NHS Trust, Leeds
  • Queen Alexandra Hospital, Portsmouth
  • The Christie Hospital, Manchester
  • The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle

Further information

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: 

https://clinicaltrials.gov/study/NCT06191744

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.